People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2018 |
| Affinivax, Inc. | — | Biotechnology | Series D+ | $233.0M | $7.8B | 2017 |
| Tyra Biosciences, Inc. | — | Biotechnology | Series D+ | $200.0M | $2.5B | 2024 |
| Sienna Biopharmaceuticals, Inc. | — | Biotechnology | Series C | $58.9M | $1.7B | 2015 |
| Nuon Therapeutics Inc | — | Biotechnology | Series A | $29.7M | $361.5M | 2010 |
| Patientkeeper Inc | — | Other Health Care | Series A | $23.2M | $18.2M | 2011 |
| Oceana Therapeutics, Inc. | — | Pharmaceuticals | Seed | $3.0M | $114.1M | 2008 |
Robert More at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert More on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ryan Drant | 2 | 24 |
| Kristina Burow | 2 | 16 |
| Robert Nelsen | 1 | 22 |
| Nina Kjellson | 1 | 11 |
| Brian Halak | 1 | 10 |
| Adele Oliva | 1 | 9 |
| Dan O'Brien | 1 | 8 |
| Robert Nelson | 1 | 7 |
| Charles M. Hazard, Jr. | 1 | 7 |
| Kim Kamdar | 1 | 6 |
| Bob More | 1 | 6 |
| Vicki Sato | 1 | 6 |
| Andrew Hack | 1 | 5 |
| Arlene Morris | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Alan Fuhrman | 1 | 5 |
| Saira Ramasastry | 1 | 4 |
| George Scangos | 1 | 4 |
| Ryan W. Drant | 1 | 4 |
| Thomas Daniel | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.